A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.

Trial Details

NCT ID
NCT06505395
Phase
PHASE2
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • SYHX2008 injection
  • Sandostatin LAR@
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Male or female patient ≥18 years old;
  • Histologically confirmed, advanced GEP-NET;
  • At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1;
  • Previous treatment with ≤2 systemic antitumor drugs;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →